See more : Integra Resources Corp. (ITRG) Income Statement Analysis – Financial Results
Complete financial analysis of Verona Pharma plc (VRNA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Verona Pharma plc, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Thumzup Media Corporation (TZUP) Income Statement Analysis – Financial Results
- Innovatus Entertainment Networ (INNOVATUS.BO) Income Statement Analysis – Financial Results
- General Electric Company (GNE.PA) Income Statement Analysis – Financial Results
- LatAmGrowth SPAC (LATG) Income Statement Analysis – Financial Results
- Pak Tak International Limited (2668.HK) Income Statement Analysis – Financial Results
Verona Pharma plc (VRNA)
About Verona Pharma plc
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 458.00K | 40.00M | 0.00 | 2.35K | 2.78K | 1.84M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 679.62K | 346.00K | 0.00 | 627.85K | 512.11K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -679.62K | 112.00K | 40.00M | -627.85K | -509.76K | 2.78K | 1.84M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 24.45% | 100.00% | 0.00% | -21,682.69% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 17.28M | 49.28M | 79.41M | 44.51M | 43.89M | 24.48M | 32.05M | 5.58M | 10.76M | 4.10M | 2.73M | 2.71M | 1.46M | 1.78M | 1.53M | 1.29M | 1.50M | 266.45K | 0.00 |
| General & Administrative | 0.00 | 7.20M | 11.66M | 29.77M | 8.99M | 7.99M | 8.10M | 2.89M | 2.51M | 1.80M | 1.91M | 1.47M | 1.12M | 1.09M | 1.05M | 827.39K | 894.40K | 1.05M | 18.93K |
| Selling & Marketing | 0.00 | 19.38M | 22.24M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 49.87M | 26.58M | 33.91M | 29.77M | 8.99M | 7.99M | 8.10M | 2.89M | 2.51M | 1.80M | 1.91M | 1.47M | 1.12M | 1.09M | 1.05M | 827.39K | 894.40K | 1.05M | 18.93K |
| Other Expenses | 0.00 | -9.63M | -15.63M | -8.27M | 527.09K | 16.50K | 23.00K | 1.07M | 1.17M | 0.00 | 0.00 | 0.00 | 268.60K | 43.22K | 11.32K | 61.51K | 196.33K | 0.00 | -113.57K |
| Operating Expenses | 67.15M | 66.23M | 97.68M | 66.01M | 53.41M | 32.48M | 40.16M | 8.49M | 13.29M | 5.90M | 4.64M | 4.18M | 2.87M | 2.93M | 2.60M | 2.17M | 2.61M | 1.31M | 12.04K |
| Cost & Expenses | 67.83M | 66.57M | 97.68M | 66.01M | 53.41M | 32.48M | 40.16M | 8.49M | 13.29M | 5.90M | 4.64M | 4.18M | 2.87M | 2.93M | 2.60M | 2.17M | 2.61M | 1.31M | 12.04K |
| Interest Income | 12.81M | 2.82M | 14.00K | 121.00K | 988.62K | 1.09M | 466.24K | 106.78K | 66.36K | 46.66K | 4.34K | 32.61K | 6.21K | 12.35K | 11.32K | 203.55K | 192.36K | 123.43K | 56.78K |
| Interest Expense | 2.06M | 521.00K | 340.00K | 35.00K | 221.59K | 0.00 | 98.65K | 104.52K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 679.62K | 636.00K | 629.00K | 627.85K | 512.11K | 124.35K | 166.22K | 76.03K | 78.69K | 82.43K | 61.99K | 49.08K | 37.26K | 32.41K | 35.57K | 27.82K | 27.76K | 3.92K | 0.00 |
| EBITDA | -52.47M | -67.29M | -42.19M | -47.81M | -32.17M | -25.50M | -29.64M | -6.96M | -8.92M | -3.74M | -2.78M | -2.56M | -2.86M | -2.88M | -2.59M | -1.94M | -2.39M | -1.19M | -12.04K |
| EBITDA Ratio | 0.00% | -13,681.00% | -142.60% | 0.00% | -2,201,821.75% | -1,123,504.50% | -2,145.59% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -67.83M | -66.12M | -73.31M | -74.28M | -53.87M | -32.47M | -40.21M | -8.66M | -13.29M | -5.90M | -4.64M | -4.18M | -2.87M | -2.93M | -2.60M | -2.17M | -2.61M | -1.31M | -12.04K |
| Operating Income Ratio | 0.00% | -14,435.81% | -183.28% | 0.00% | -2,291,221.96% | -1,166,819.68% | -2,184.27% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 12.62M | 7.30M | -1.37M | 6.78M | 8.99M | 1.46M | 4.55M | 1.05M | -28.00K | 29.98K | 2.63K | 32.61K | 6.21K | 12.35K | 11.32K | 203.55K | 192.36K | 123.43K | 56.78K |
| Income Before Tax | -55.21M | -68.45M | -55.59M | -65.00M | -51.41M | -30.62M | -34.06M | -7.37M | -13.22M | -5.86M | -4.64M | -4.15M | -2.86M | -2.91M | -2.59M | -1.97M | -2.41M | -1.19M | 44.74K |
| Income Before Tax Ratio | 0.00% | -14,944.98% | -138.97% | 0.00% | -2,186,540.61% | -1,100,342.28% | -1,850.05% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -632.44K | 253.00K | -18.00K | 146.00K | -9.53M | -5.37M | -6.36M | -1.18M | -2.24M | -1.56M | -477.22K | -77.68K | -192.52K | 7.72K | -24.25K | 41.00K | 192.36K | 123.43K | 0.00 |
| Net Income | -54.37M | -68.70M | -55.57M | -65.15M | -41.88M | -25.25M | -27.70M | -6.19M | -10.99M | -4.29M | -4.16M | -4.07M | -2.67M | -2.92M | -2.59M | -2.01M | -2.41M | -1.19M | 44.74K |
| Net Income Ratio | 0.00% | -15,000.22% | -138.92% | 0.00% | -1,781,367.49% | -907,384.56% | -1,504.60% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.54 | -1.04 | -0.94 | -1.98 | -3.18 | -0.19 | -0.25 | 0.00 | -0.01 | 0.00 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | 0.00 |
| EPS Diluted | -0.54 | -1.04 | -0.94 | -1.98 | -3.18 | -0.19 | -0.25 | 0.00 | -0.01 | 0.00 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | 0.00 |
| Weighted Avg Shares Out | 79.27M | 66.13M | 59.15M | 32.87M | 13.17M | 131.39M | 109.69M | 2.09B | 1.26B | 1.08B | 426.96M | 383.28M | 304.31M | 298.45M | 269.43M | 261.38M | 180.51M | 96.58M | 55.94M |
| Weighted Avg Shares Out (Dil) | 79.27M | 66.13M | 59.15M | 32.87M | 13.17M | 131.39M | 109.69M | 2.09B | 1.26B | 1.08B | 426.96M | 383.28M | 304.31M | 298.45M | 269.43M | 261.38M | 180.51M | 96.58M | 68.26M |
Verona Pharma Announces December 2024 Investor Conference Participation
LONDON and RALEIGH, N.C., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the following conferences in December 2024:
Caligan picks up a stake in Verona Pharma, seeing an opportunity to generate more value
Verona Pharma has seen its share price skyrocket in anticipation of the commercial launch of its COPD treatment.
Verona Pharma to Present at Jefferies London Healthcare Conference
LONDON and RALEIGH, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024,...
Verona Pharma plc (VRNA) Q3 2024 Earnings Call Transcript
Verona Pharma plc (NASDAQ:VRNA ) Q3 2024 Earnings Conference Call November 4, 2024 9:00 AM ET Company Participants David Zaccardelli - President and Chief Executive Officer Mark Hahn - Chief Financial Officer Christopher Martin - Chief Commercial Officer Tara Rheault...
Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Ohtuvayre™ (ensifentrine) launch recorded Q3 net sales of $5.6 million and October net sales exceeded Q3
Recent Price Trend in Verona Pharma (VRNA) is Your Friend, Here's Why
Verona Pharma (VRNA) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
5 Biotech Stocks Likely to Outperform as Industry Prospects Look Bright
New drug approvals and strong pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position EXEL, BPMC, CRSP, FOLD and VRNA well in this volatile sector.
Verona Pharma to Report Third Quarter 2024 Financial Results and Provide Corporate Update
LONDON and RALEIGH, N.C., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the third quarter ended September 30, 2024 on Monday, November 4,...
Wall Street Analysts Think Verona Pharma (VRNA) Could Surge 25.25%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 25.3% in Verona Pharma (VRNA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into...
Verona Pharma (VRNA) Is a Great Choice for 'Trend' Investors, Here's Why
Verona Pharma (VRNA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength"...
Source: https://incomestatements.info
Category: Stock Reports